Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 19/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4605681 | 0.92 | CCR3 (0.47) | CCR3RAB9A | |
| SCHEMBL4662519 | 0.90 | RAB9A (0.52) | CCR3RAB9A | |
| SCHEMBL4604415 | 0.87 | PORCN (0.47) | CCR3 | |
| SCHEMBL5908177 | 0.87 | ALDH1A1 (0.44) | CCR3CYP2D6 | |
| SCHEMBL4768262 | 0.84 | CYP1A2 (0.55) | CCR3CYP2D6 | |
| SCHEMBL4437613 | 0.84 | CYP1A2 (0.53) | CCR3 | |
| SCHEMBL4606931 | 0.83 | ALDH1A1 (0.44) | — | |
| SCHEMBL4603897 | 0.82 | CYP1A2 (0.45) | CCR3 | |
| SCHEMBL6083827 | 0.82 | ABCC9 (0.55) | — | |
| SCHEMBL4606481 | 0.81 | ALDH1A1 (0.41) | CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682105-A4 | N-UREIDOALKYL-AMINO COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | WEIGAND KLAUS | 2008-12-11 | — | — | US | disclosed |
| EP-1976836-A2 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | Amgen Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| EP-1943235-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Novartis AG (CH) | 2008-07-16 | — | — | EP | disclosed |
| US-7291744-B2 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291744-B2 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| WO-2007076092-A2 | NITROGEN- CONTAINING BICYCLIC HETROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | AMGEN INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-7230022-B2 | Substituted fused bicyclic amines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| WO-2007048771-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2007-05-03 | — | — | WO | disclosed |
| EP-1682105-A2 | N-UREIDOALKYL-AMINO COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050197373-A1 | Substituted fused bicyclic amines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-08 | — | — | US | disclosed |
| WO-2005079497-A2 | SUBSTITUTED FUSED BICYCLIC AMINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
| US-6919356-B2 | N-substituted heterocyclic amines as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| US-20050153970-A1 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-07-14 | — | — | US | disclosed |
| EP-1545524-A2 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY. | Bristol-Myers Squibb Company (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2005048932-A2 | N-UREIDOALKYL-AMINO COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
| US-20040082616-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-29 | — | — | US | disclosed |
| WO-2004028530-A1 | N-SUBSTITUTED HETEROCYCLIC AMINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-08 | — | — | WO | disclosed |
| US-20040067935-A1 | N-substituted heterocyclic amines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-08 | — | — | US | disclosed |
| WO-2004024682-A2 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY. | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | CCR3, CCR1, CCR4 | CCR3 1/4885RAB9A 2140/4885CYP2D6 2500/4885 |
| US-20050153970-A1 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | ACKR3, CCL11, GPR17 | CCR3 18/4885RAB9A 1021/4885CYP2D6 3192/4885 |
| US-20040082616-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | ACKR3, CCL11, CCR2 | CCR3 13/4885RAB9A 1051/4885CYP2D6 4419/4885 |
| US-20050197373-A1 | Substituted fused bicyclic amines as modulators of chemokine receptor activity | CCR3, CCR1, CCR2 | CCR3 1/4885RAB9A 966/4885CYP2D6 2430/4885 |
| US-20040067935-A1 | N-substituted heterocyclic amines as modulators of chemokine receptor activity | CCL11, ACKR3, CCR7 | CCR3 19/4885RAB9A 997/4885CYP2D6 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.